Research ArticleOriginal Articles
Open Access

Low versus standard dose intravenous alteplase in the treatment of acute ischemic stroke in Egyptian patients

Gelan M. Salem, Wafik M. El-Sheik, Basma G. El-shanawany and Khaled H. Afifi
Neurosciences Journal April 2021, 26 (2) 179-185; DOI: https://doi.org/10.17712/nsj.2021.2.20200148

References

  1. 1.↵
    1. Macrez R,
    2. Ali C,
    3. Toutirais O,
    4. Le Mauff B,
    5. Defer G,
    6. Dirnagl U, et al.
    Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurology 2011; 10: 471–480.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    National Institute of Neurological Disorders and Stroke rt-PA Stroke Study. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Wahlgren N,
    2. Ahmed N,
    3. Dávalos A,
    4. Ford GA,
    5. Grond M,
    6. Hacke W, et al.
    Thrombolysis with alteplase for acute ischemic stroke in the Safe Implementation of Thrombolysis in Stroke- Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275–282.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Hacke W,
    2. Kaste M,
    3. Bluhmki E,
    4. Brozman M,
    5. Dávalos A,
    6. Guidetti D, et al.
    Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke (ECASS III). N Engl J Med 2008; 359: 1317–1329.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Chiu D,
    2. Krieger D,
    3. Villar-Cordova C,
    4. Kasner SE,
    5. Morgenstern LB,
    6. Bratina PL, et al.
    Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998; 29: 18–22.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Liu MD,
    2. Ning WD,
    3. Wang RC,
    4. Chen W,
    5. Yang Y,
    6. Lin Y, et al.
    Low-dose versus standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a meta-analysis. Medicine 2015; 94: e2412.
    OpenUrlPubMed
  7. 7.↵
    1. Yamaguchi T,
    2. Mori E,
    3. Minematsu K,
    4. Nakagawara J,
    5. Hashi K,
    6. Saito I et al
    : Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810–1815.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    1. Nakagawara J,
    2. Minematsu K,
    3. Okada Y,
    4. Tanahashi N,
    5. Nagahiro S,
    6. Mori E, et al.
    Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984–1989.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Mori E,
    2. Yoneda Y,
    3. Tabuchi M,
    4. Yoshida T,
    5. Ohkawa S,
    6. Ohsumi Y, et al.
    Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976–976.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Yamaguchi T,
    2. Mori E,
    3. Minematsu K,
    4. Nakagawara J,
    5. Hashi K,
    6. Saito I, et al.
    Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810–1815.
    OpenUrlAbstract/FREE Full Text
  11. 11.
    1. Abd Allah F,
    2. Baligh E,
    3. Ibrahim M
    . Clinical relevance of carotid atherosclerosis among Egyptians: a 5-year retrospective analysis of 4,733 subjects. Neuroepidemiology 2010; 35: 275–27s9.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Zakaria MF,
    2. Aref H,
    3. Abd ElNasser A,
    4. Fahmy N,
    5. Tork M,
    6. Fouad M, et al.
    Egyptian experience in increasing utilization of reperfusion therapies in acute ischemic stroke. Int J Stroke 2018; 13: 525–529.
    OpenUrl
  13. 13.↵
    1. Powers WJ,
    2. Rabinstein AA,
    3. Ackerson, T., et al.
    2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49: e46–e99.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Barber PA,
    2. Demchuk AM,
    3. Zhang J,
    4. Adeoye OM,
    5. Bambakidis NC,
    6. Becker K, et al.
    The validity and reliability of a novel quantitative CT score in predicting outcome in hyperacute stroke prior to thrombolytic therapy. Lancet 2000; 355: 1670–1674.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Bamford J,
    2. Sandercock P,
    3. Dennis M,
    4. Burn J,
    5. Warlow C
    . Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521–1526.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Adams H,
    2. Bendixen B,
    3. Kappelle L
    . Classification of subtype of acute ischemic stroke Definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Hage V
    . “The NIH stroke scale: a window into neurological status”. Nursing Spectrum 2011; 24: 44–49.
    OpenUrl
  18. 18.↵
    1. Kim B J,
    2. Han MK,
    3. Park TH,
    4. Park SS,
    5. Lee KB,
    6. Lee BC, et al.
    Low-versus standard-dose alteplase for ischemic strokes within 4.5 hours: a comparative effectiveness and safety study. Stroke 2015; 46: 2541–2548.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Chao AC,
    2. Liu CK,
    3. Chen CH,
    4. Lin HJ,
    5. Liu CH,
    6. Jeng JS, et al.
    Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients. Stroke 2014; 45: 2359–2365.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Anderson CS,
    2. Robinson T,
    3. Lindley RI,
    4. Arima H,
    5. Lavados PM,
    6. Lee T, et al.
    Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med 2016; 374: 2313–2323.
    OpenUrlPubMed
  21. 21.↵
    1. Nguyen TH,
    2. Truong AL,
    3. Ngo MB,
    4. Bui CT,
    5. Dinh QV,
    6. Doan TC, et al.
    Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry. Eur J Neurol 2010; 17: 1188–1192.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Sharma VK,
    2. Kawnayn G,
    3. Sarkar N
    . Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator. Expert Rev Neurother 2013; 13: 895–902.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Yang J,
    2. Yu F,
    3. Liu H,
    4. An H,
    5. Xiong R,
    6. Huang D
    . A retrospective study of thrombolysis with 0.6 mg/kg recombinant tissue plasminogen activator (rt-PA) in mild stroke. Sci Rep 2016; 6: 31344.
    OpenUrl
  24. 24.↵
    1. Zhou XY,
    2. Wanga SS,
    3. Collins ML,
    4. Davis SM,
    5. Yan B
    . Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci 2010; 17: 988–992.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Zakaria MF,
    2. Aref H,
    3. Abd ElNasser A,
    4. Fahmy N,
    5. Tork MA,
    6. Fouad MM, et al.
    Egyptian experience in increasing utilization of reperfusion therapies in acute ischemic stroke. Int J Stroke 2018; 13: 525–529.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section